PTCT · Categories · Downgrades
PTCT - Analyst downgrades
PTC Therapeutics Inc. (PTCT) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for PTCT
- PTC Therapeutics downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded PTC Therapeutics from Outperform to Sector Perform and set a new price target of $91.00
- PTC Therapeutics downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded PTC Therapeutics from Equal-Weight to Underweight and set a new price target of $28.00
- PTC Therapeutics downgraded by Citigroup with a new price targetCitigroup downgraded PTC Therapeutics from Neutral to Sell and set a new price target of $17.00 from $29.00 previously
- PTC Therapeutics downgraded by Truist with a new price targetTruist downgraded PTC Therapeutics from Buy to Hold and set a new price target of $25.00 from $45.00 previously
- PTC Therapeutics downgraded by Citigroup with a new price targetCitigroup downgraded PTC Therapeutics from Buy to Neutral and set a new price target of $28.00 from $55.00 previously
- PTC Therapeutics downgraded by Raymond JamesRaymond James downgraded PTC Therapeutics from Outperform to Underperform
- PTC Therapeutics downgraded by B of A Securities with a new price targetB of A Securities downgraded PTC Therapeutics from Neutral to Underperform and set a new price target of $38.00
- PTC Therapeutics downgraded by Bank of AmericaBank of America downgraded PTC Therapeutics from Buy to Neutral